Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (RCUS) will host an in-person investor event with live webcast on October 20, 2026, at 8:30 AM ET in New York City to present new ARC-20 study data for casdatifan in clear cell renal cell carcinoma across first-, second- and late-line settings.
Presentations will cover casdatifan combinations with zimberelimab and ipilimumab as first-line TKI-free regimens, a second-line TKI-containing combination with cabozantinib, and late-line monotherapy, including safety, overall response rate, progression-free survival and overall survival readouts. Data are intended to inform and support registrational trials PEAK-20 and PEAK-1, as well as Arcus's strategy to position casdatifan as a backbone therapy in ccRCC.
Arcus Biosciences (RCUS) granted equity inducement awards to one new employee under its 2020 Inducement Plan. The awards consist of options to purchase 26,350 shares of common stock at an exercise price of $29.06 per share, equal to the closing price on September 8, 2026, and restricted stock units covering 13,200 shares of common stock.
The grants were approved by the Compensation Committee of the Board of Directors and made pursuant to the company’s 2020 Inducement Plan, which was approved in January 2020 under the NYSE Listed Company Manual Rule 303A.08 “inducement exception.”
Arcus Biosciences (NYSE:RCUS) announced participation in three investor conferences in September 2026. Management will appear at Citi’s 2026 Biotech Back to School Conference on September 9, the Cantor Fitzgerald Global Healthcare Conference 2026 on September 10, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, all in New York, featuring fireside chats and 1x1 meetings. Live webcasts and replays will be accessible via the company’s Investors & Media webpage.
Arcus Biosciences (NYSE:RCUS) reported that the Compensation Committee of its Board of Directors has granted equity awards to one new employee under the company’s 2020 Inducement Plan. The awards consist of options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share, equal to the August 10, 2026 closing price, and restricted stock units covering 1,450 shares of common stock. The 2020 Inducement Plan was approved by the Board in January 2020 pursuant to the NYSE “inducement exception” under Rule 303A.08.
Arcus Biosciences (NYSE:RCUS) reported second-quarter 2026 revenue of $41 million, down from $160 million a year earlier, R&D expenses of $113 million and G&A expenses of $24 million, resulting in a net loss of $91 million. Cash, cash equivalents and marketable securities totaled $775 million at June 30, 2026, with an expected year-end 2026 balance of about $600 million and projected cash runway into at least the second half of 2028.
Arcus is prioritizing its HIF-2α inhibitor casdatifan/b) as a backbone therapy for clear cell renal cell carcinoma across treatment lines, supported by a Nature publication, multiple ARC-20 data readouts expected in 2026, the PEAK-1 Phase 3 trial, and new clinical collaborations with Bristol Myers Squibb, Summit Therapeutics and AVEO Oncology. The company also highlighted progress in its quemliclustat pancreatic cancer program, an expanding small-molecule immunology portfolio, and the wind-down of domvanalimab-based anti-TIGIT Phase 3 trials and related Gilead board representation.
Arcus Biosciences (NYSE:RCUS) reported that the Compensation Committee of its Board of Directors granted inducement equity awards to three new employees under the company’s 2020 Inducement Plan. The awards consist of options to purchase a total of 12,600 shares of common stock at an exercise price of $29.73 per share, which equals the closing price on July 23, 2026, and restricted stock units covering a total of 6,300 shares of common stock.
According to the company, these grants were made pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08, following approval of the plan by the Board of Directors in January 2020.
Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate Arcus’s investigational HIF-2α inhibitor casdatifan (AB521) in combination with AVEO’s VEGFR TKI tivozanib (FOTIVDA) in advanced clear cell renal cell carcinoma (ccRCC).
The agreement supports a new randomized cohort within the ongoing ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) versus tivozanib (1.34 mg) alone in patients with advanced ccRCC previously treated with a HIF-2α inhibitor. AVEO will supply tivozanib, while Arcus will sponsor and conduct the study; each company retains development and commercial rights to its own compound. Enrollment for this cohort is expected to begin in the fourth quarter of 2026. Casdatifan is being developed as a potential backbone therapy across first- and second-line metastatic ccRCC settings, including the global Phase 3 PEAK-1 study of casdatifan plus cabozantinib versus cabozantinib alone.
Arcus Biosciences (NYSE: RCUS) and Summit Therapeutics (Nasdaq: SMMT) entered a clinical trial collaboration to evaluate Arcus’s HIF-2α inhibitor casdatifan (AB521) combined with Summit’s PD‑1/VEGF bispecific antibody ivonescimab in clear cell renal cell carcinoma, including first-line metastatic disease.
Arcus will sponsor and conduct a new combination cohort within its ARC‑20 platform study; Summit will supply ivonescimab. Both companies will share study costs and retain development and commercialization rights to their respective molecules. Initial data from this combination are expected by mid‑2027, adding to Arcus’s broader casdatifan program and Summit’s growing ivonescimab franchise.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on Wednesday, August 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss second-quarter 2026 financial results and pipeline updates. Investors can join via phone, online registration, or live webcast with a replay available.
Arcus Biosciences (NYSE:RCUS) announced new employment inducement equity awards granted by its board’s Compensation Committee. Five new employee stock options for a total of 16,060 shares were issued with an exercise price of $30.26, the July 8, 2026 closing price, plus 8,080 RSUs. These grants were made under the company’s 2020 Inducement Plan, adopted in January 2020 pursuant to the NYSE “inducement exception” under Rule 303A.08.